



Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

OPEN ACCESS

Approved by:

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Feihong Luo
luofh@fudan.edu.cn
Ruoqian Cheng
chengrq78@163.com

[†]These authors have contributed
equally to this work and
share first authorship

Specialty section:

This article was submitted to
Pediatric Endocrinology,
a section of the journal
Frontiers in Endocrinology

Received: 07 December 2021

Accepted: 09 December 2021

Published: 28 December 2021

Citation:

Sun C, Lu B, Liu Y, Zhang Y,
Wei H, Hu X, Hu P, Zhao Q,
Liu Y, Ye K, Wang K, Gu Z, Liu Z,
Ye J, Zhang H, Zhu H, Jiang Z,
Liu Y, Wan N, Yan C, Yin J, Ying L,
Huang F, Yin Q, Xi L, Luo F and
Cheng R (2021) Corrigendum:
Reduced Effectiveness and
Comparable Safety in Biweekly vs.
Weekly PEGylated Recombinant
Human Growth Hormone for
Children With Growth Hormone
Deficiency: A Phase IV Non-Inferiority
Threshold Targeted Trial.
Front. Endocrinol. 12:830469.
doi: 10.3389/fendo.2021.830469

Chengjun Sun^{1†}, Biao Lu^{2†}, Yu Liu^{3†}, Yaqin Zhang⁴, Haiyan Wei⁵, Xu Hu⁶, Pei Hu⁷,
Qian Zhao⁷, Yanling Liu⁸, Kan Ye⁹, Kan Wang¹⁰, Zaiyan Gu¹¹, Zheng Liu¹², Jin Ye¹³,
Hongxiao Zhang¹⁴, Hong Zhu¹⁵, Zhihong Jiang¹⁶, Yanjie Liu¹⁷, Naijun Wan¹⁸,
Chengming Yan¹⁹, Jianying Yin²⁰, Lirong Ying²¹, Feng Huang²², Qingjin Yin²³, Li Xi¹,
Feihong Luo^{1*} and Ruoqian Cheng^{1*}

¹ Department of Pediatric Endocrinology and Inherited Metabolic Diseases, Children's Hospital of Fudan University, Shanghai, China, ² Department of Pediatrics, General Hospital of Ningxia Medical University, Yinchuan, China, ³ Department of Endocrine and Genetic Metabolism, Maternal and Child Health-Care Hospital in Guiyang, Guiyang, China, ⁴ Department of Child Health, Maternal and Child Health Care Hospital of Hainan Province, Haikou, China, ⁵ Department of Pediatric Endocrinology and Inherited Metabolic Diseases, Henan Provincial Hospital, Affiliated to Zhengzhou University, Zhengzhou, China, ⁶ Department of Pediatrics, Lu'an People's Hospital, Lu'an, China, ⁷ Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, National Medical Products Administration (NMPA) Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical Pharmacokinetics and Pharmacodynamics (PK & PD) Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁸ Department of Pediatrics, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁹ Department of Child Health, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China, ¹⁰ Department of Pediatrics, Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China, ¹¹ Department of Pediatrics, Jiaying First Hospital, Jiaying, China, ¹² Department of Pediatrics, Tai'an Maternal and Child Health Care Hospital, Tai'an, China, ¹³ Department of Pediatrics, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China, ¹⁴ Department of Pediatrics, Second Hospital of Lanzhou University, Lanzhou, China, ¹⁵ Department of Pediatrics, The First People's Hospital of Changzhou, Changzhou, China, ¹⁶ Department of Pediatrics, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹⁷ Department of Pediatrics, Inner Mongolia People's Hospital, Hohhot, China, ¹⁸ Department of Pediatrics, Jishuitan Hospital, Beijing, China, ¹⁹ Department of Pediatrics, Anhui Province Maternity and Child Health Hospital, Anhui Medical University Maternal and Child Health Clinic College, Hefei, China, ²⁰ Department of Pediatrics, Hebei General Hospital, Shijiazhuang, China, ²¹ Department of Pediatrics, Cixi People's Hospital, Cixi, China, ²² Department of Pediatrics, Affiliated Hospital of Nantong University, Nantong, China, ²³ Department of Internal Medicine, Chengdu Children's Specialized Hospital, Chengdu, China

Keywords: growth hormone deficiency, PEGylated recombinant human growth hormone, PEG-rhGH, IGF-2, children

A Corrigendum on:**Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial**

by Sun, C., Lu, B., Liu, Y., Zhang, Y., Wei, H., Hu, X., Hu, P., Zhao, Q., Liu, Y., Ye, K., Wang, K., Gu, Z., Liu, Z., Ye, J., Zhang, H., Zhu, H., Jiang, Z., Liu, Y., Wan, N., Yan, C., Yin, J., Ying, L., Huang, F., Yin, Q., Xi, L., Luo, F. and Cheng, R. (2021) *Front. Endocrinol.* 12:779365. doi: 10.3389/fendo.2021.779365

The second and third authors, Biao Lu and Yu Liu, were not listed as co-first-authors in the article as published originally.

The Author Contributions statement, published originally read “FL and RC conceived the study design, managed the study, conducted the data analysis, and wrote the manuscript. CS helped with the data analysis and editing of the manuscript. LX, BL, YL, YZ, HW, XH, PH, QZ, YLL, KY, KW, ZG, ZL, JY, HXZ, HZ, ZJ, YJL, NW, CY, JYY, LY, FH, and QY are site investigators and conducted the study in each participating center. All authors contributed to the article and approved the submitted version”. The corrected Author Contributions statement is as follows: “FL and RC conceived the study

design, managed the study, conducted the data analysis, and wrote the manuscript. CS helped with the data analysis and editing of the manuscript. BL and YL contributed to the design of the study protocol, training of trial investigators. LX, BL, YL, YZ, HW, XH, PH, QZ, YLL, KY, KW, ZG, ZL, JY, HXZ, HZ, ZJ, YJL, NW, CY, JYY, LY, FH, and QY are site investigators and conducted the study in each participating center. All authors contributed to the article and approved the submitted version.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Sun, Lu, Liu, Zhang, Wei, Hu, Hu, Zhao, Liu, Ye, Wang, Gu, Liu, Ye, Zhang, Zhu, Jiang, Liu, Wan, Yan, Yin, Ying, Huang, Yin, Xi, Luo and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.